These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1219 related articles for article (PubMed ID: 27836739)

  • 21. The 4-1BB ligand and 4-1BB expressed on osteoclast precursors enhance RANKL-induced osteoclastogenesis via bi-directional signaling.
    Yang J; Park OJ; Lee YJ; Jung HM; Woo KM; Choi Y
    Eur J Immunol; 2008 Jun; 38(6):1598-609. PubMed ID: 18421790
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A novel small molecule, NecroX-7, inhibits osteoclast differentiation by suppressing NF-κB activity and c-Fos expression.
    Kim HJ; Yoon KA; Lee MK; Kim SH; Lee IK; Kim SY
    Life Sci; 2012 Nov; 91(19-20):928-34. PubMed ID: 23000100
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Acteoside suppresses RANKL-mediated osteoclastogenesis by inhibiting c-Fos induction and NF-κB pathway and attenuating ROS production.
    Lee SY; Lee KS; Yi SH; Kook SH; Lee JC
    PLoS One; 2013; 8(12):e80873. PubMed ID: 24324641
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Docosahexaenoic acid is more potent inhibitor of osteoclast differentiation in RAW 264.7 cells than eicosapentaenoic acid.
    Rahman MM; Bhattacharya A; Fernandes G
    J Cell Physiol; 2008 Jan; 214(1):201-9. PubMed ID: 17929247
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Macrolactin F inhibits RANKL-mediated osteoclastogenesis by suppressing Akt, MAPK and NFATc1 pathways and promotes osteoblastogenesis through a BMP-2/smad/Akt/Runx2 signaling pathway.
    Li L; Sapkota M; Gao M; Choi H; Soh Y
    Eur J Pharmacol; 2017 Nov; 815():202-209. PubMed ID: 28919027
    [TBL] [Abstract][Full Text] [Related]  

  • 26. DICAM inhibits osteoclast differentiation through attenuation of the integrin αVβ3 pathway.
    Jung YK; Han SW; Kim GW; Jeong JH; Kim HJ; Choi JY
    J Bone Miner Res; 2012 Sep; 27(9):2024-34. PubMed ID: 22492581
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Norisoboldine suppresses osteoclast differentiation through preventing the accumulation of TRAF6-TAK1 complexes and activation of MAPKs/NF-κB/c-Fos/NFATc1 Pathways.
    Wei ZF; Tong B; Xia YF; Lu Q; Chou GX; Wang ZT; Dai Y
    PLoS One; 2013; 8(3):e59171. PubMed ID: 23536866
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Kalkitoxin Reduces Osteoclast Formation and Resorption and Protects against Inflammatory Bone Loss.
    Li L; Yang M; Shrestha SK; Kim H; Gerwick WH; Soh Y
    Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33669069
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Purslane suppresses osteoclast differentiation and bone resorbing activity via inhibition of Akt/GSK3β-c-Fos-NFATc1 signaling in vitro and prevents lipopolysaccharide-induced bone loss in vivo.
    Kim JY; Oh HM; Kwak SC; Cheon YH; Lee MS; Rho MC; Oh J
    Biol Pharm Bull; 2015; 38(1):66-74. PubMed ID: 25744460
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pyridone 6, a pan-Janus-activated kinase inhibitor, suppresses osteoclast formation and bone resorption through down-regulation of receptor activator of nuclear factor-kappaB (NF-kappaB) ligand (RANKL)-induced c-Fos and nuclear factor of activated T cells (NFAT) c1 expression.
    Kwak HB; Kim HS; Lee MS; Kim KJ; Choi EY; Choi MK; Kim JJ; Cho HJ; Kim JW; Bae JM; Kim YK; Park BH; Ha H; Chun CH; Oh J
    Biol Pharm Bull; 2009 Jan; 32(1):45-50. PubMed ID: 19122279
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1.
    Takatsuna H; Asagiri M; Kubota T; Oka K; Osada T; Sugiyama C; Saito H; Aoki K; Ohya K; Takayanagi H; Umezawa K
    J Bone Miner Res; 2005 Apr; 20(4):653-62. PubMed ID: 15765185
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chlorogenic acid inhibits osteoclast differentiation and bone resorption by down-regulation of receptor activator of nuclear factor kappa-B ligand-induced nuclear factor of activated T cells c1 expression.
    Kwak SC; Lee C; Kim JY; Oh HM; So HS; Lee MS; Rho MC; Oh J
    Biol Pharm Bull; 2013; 36(11):1779-86. PubMed ID: 23985829
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Total saponin from Anemone flaccida Fr. Schmidt abrogates osteoclast differentiation and bone resorption via the inhibition of RANKL-induced NF-κB, JNK and p38 MAPKs activation.
    Kong X; Wu W; Yang Y; Wan H; Li X; Zhong M; Zhao H; Su X; Jia S; Ju D; Lin N
    J Transl Med; 2015 Mar; 13():91. PubMed ID: 25889035
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A natural compound (LCA) isolated from Litsea cubeba inhibits RANKL-induced osteoclast differentiation by suppressing Akt and MAPK pathways in mouse bone marrow macrophages.
    Yu L; Jia D; Feng K; Sun X; Xu W; Ding L; Xin H; Qin L; Han T
    J Ethnopharmacol; 2020 Jul; 257():112873. PubMed ID: 32298753
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Arctigenin suppresses receptor activator of nuclear factor κB ligand (RANKL)-mediated osteoclast differentiation in bone marrow-derived macrophages.
    Kim AR; Kim HS; Lee JM; Choi JH; Kim SN; Kim DK; Kim JH; Mun SH; Kim JW; Jeon HS; Kim YM; Choi WS
    Eur J Pharmacol; 2012 May; 682(1-3):29-36. PubMed ID: 22387094
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cell adhesion signaling regulates RANK expression in osteoclast precursors.
    Mochizuki A; Takami M; Miyamoto Y; Nakamaki T; Tomoyasu S; Kadono Y; Tanaka S; Inoue T; Kamijo R
    PLoS One; 2012; 7(11):e48795. PubMed ID: 23139818
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Parthenolide inhibits osteoclast differentiation and bone resorbing activity by down-regulation of NFATc1 induction and c-Fos stability, during RANKL-mediated osteoclastogenesis.
    Kim JY; Cheon YH; Yoon KH; Lee MS; Oh J
    BMB Rep; 2014 Aug; 47(8):451-6. PubMed ID: 24314143
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diarylheptanoid from Curcuma comosa Roxb. suppresses RANKL-induced osteoclast differentiation by decreasing NFATc1 and c-Fos expression via MAPK pathway.
    Chawalitpong S; Sornkaew N; Suksamrarn A; Palaga T
    Eur J Pharmacol; 2016 Oct; 788():351-359. PubMed ID: 27523282
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cysteine proteinase inhibitors regulate human and mouse osteoclastogenesis by interfering with RANK signaling.
    Strålberg F; Henning P; Gjertsson I; Kindlund B; Souza PP; Persson E; Abrahamson M; Kasprzykowski F; Grubb A; Lerner UH
    FASEB J; 2013 Jul; 27(7):2687-701. PubMed ID: 23572233
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Euphorbia factor L1 inhibits osteoclastogenesis by regulating cellular redox status and induces Fas-mediated apoptosis in osteoclast.
    Hong SE; Lee J; Seo DH; In Lee H; Ri Park D; Lee GR; Jo YJ; Kim N; Kwon M; Shon H; Kyoung Seo E; Kim HS; Young Lee S; Jeong W
    Free Radic Biol Med; 2017 Nov; 112():191-199. PubMed ID: 28774817
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 61.